Dendritic Cell (DC) for Immunotherapy Development

Creative Biolabs is a global company that focuses on cell therapy discovery and development. With our extensive experience and unique platform, we can provide a series of DC therapy consultation services basing on a wide variety of state-of-art technologies. We are proud to partner with our clients on the journey of bringing your novel DC therapy to the market.

Introduction to Dendritic Cell (DC) Therapy

Dendritic cells (DCs) are a family of antigen-presenting cells (APCs) that play an important role in mediating cell and humoral immune responses when binds with specific antigens. Previous studies have demonstrated that DCs can activate a number of cell types, such as natural killer (NK) cells, to trigger immune reactions against various diseases, especially for tumors. As a result, DC-based immunotherapies have been developed for inducing strong anti-tumor immune responses in animal models or clinical trials. Among them, DC vaccines have become an attractive tool for treating cancers due to their strong effectiveness in T cell activation. However, recent researchers have revealed that the DC-based cell therapies still need to be further evaluated by different ways to ensure a positive anti-tumor immunity in patients. Ex vivo and in vivo strategies are essential to analyze the expression level of DCs in tumor cells, the entrance of DCs to tumor antigens, as well as the ability of tumor cells to activate intratumoral DCs.

Overview of immunological changes observed upon moDC therapy. Fig.1 Overview of immunological changes observed upon moDC therapy. (Huber, 2018)

Our Services for Dendritic Cell (DC) Therapy

Creative Biolabs recognizes the importance of data verification and decision-making in DC therapy. The projects in this field will be evaluated comprehensively by our advanced technologies. Currently, we have developed a wide variety of DC therapy solutions that encompass data checking, project consultation, strategy optimization, as well as commercialization support. In our company, we are capable of providing an integrated assess project value assessment, from project design, experimental feasibility to commercialization possibilities to reduce investment risk, avoid pitfalls, save the cost, and speed up the project process. Meanwhile, we can also identify the most effective protocol for discovering novel DC therapy for treating different kinds of human diseases, especially for tumors. Collaborated with our experts, our protocols will meet the requirement of drug strategic and regulatory planning, such as IND application, GLP compliance. In addition, we can effectively promote the progress of DC therapy commercialization. Among them, the price, market access methods, and value proposition development will be further analyzed by our multidisciplinary team.

By continuing to grow in response to the requirements of our clients, Creative Biolabs is dedicated to offering the most comprehensive, integrated DC therapy solutions, such as data verification, project design, risk assessment, in this field. If you are interested in our services, please feel free to contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.

Reference

  1. Huber, A.; et al. Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets? Front Immunol. 2018, 9: 2804.
For Research Use Only

Let's Get Started

Contact Us

USA

UK

Follow us on

Copyright © 2022 Creative Biolabs. All Rights Reserved.